8-K: Rogers Corporation Reports Q2 2025 Loss Amid Significant Impairment Charges and Cost Reduction Initiatives

Rogers Corporation reported a substantial net loss in Q2 2025 driven by significant non-cash impairment charges, while announcing new cost reduction initiatives and providing Q3 guidance.

Summary

• Net sales for Q2 2025 were $202.8 million, representing a 6.5% sequential increase from $190.5 million in Q1 2025, but a decrease from $214.2 million in Q2 2024.
• Gross margin improved sequentially to 31.6% from 29.9% in the prior quarter, though it was lower than 34.1% in Q2 2024.
• A net loss of $73.6 million was recorded for Q2 2025, a significant widening from a $1.4 million loss in Q1 2025 and an $8.1 million net income in Q2 2024.
• The net loss includes $71.8 million of non-cash impairment charges and $4.3 million of restructuring expenses.
• Adjusted earnings per share increased 25.9% sequentially to $0.34 from $0.27.
• New cost reduction initiatives were announced for the curamik reporting unit within the Advanced Electronics Solutions (AES) segment, expected to reduce annual manufacturing costs and operating expenses by over $13.0 million.
• Total restructuring charges related to these new actions are anticipated to be between $12.0 million and $20.0 million, comprising employee severance, property, plant and equipment relocation/reinstallation, consulting fees, and other miscellaneous cash costs.
• The bulk of cash outflows for these initiatives are expected in 2026, with some occurring in the second half of 2025.
• Guidance for Q3 2025 includes net sales of $200 million to $215 million, gross margin of 31.5% to 33.5%, GAAP earnings per diluted share of $0.00 to $0.40, and adjusted earnings per diluted share of $0.50 to $0.90.
• Projected capital expenditures for 2025 are between $30 million and $40 million.

Sentiment

Score: 4

Explanation: While there are sequential improvements in some operational metrics and a clear plan for future cost reductions, the substantial net loss driven by a large non-cash impairment charge and increased restructuring expenses indicates significant underlying challenges in the curamik business unit. The overall financial picture is negative despite management's positive framing of sequential improvements and future outlook.

Positives

• Net sales increased 6.5% sequentially to $202.8 million in Q2 2025.
• Gross margin improved 170 basis points sequentially to 31.6%.
• Adjusted earnings per share increased 25.9% sequentially to $0.34.
• Net cash provided by operating activities was $13.7 million, an increase from $11.7 million in the prior quarter.
• Free cash flow improved to $5.6 million from $2.1 million sequentially.
• Repurchased $28.1 million of shares in Q2 2025, leveraging a strong balance sheet.
• New cost savings initiatives in the curamik business are expected to reduce annual run-rate costs by over $13.0 million.
• Management anticipates further improvement in Q3 results driven by slightly higher sales and cost reduction measures.

Negatives

• Reported a significant net loss of $73.6 million in Q2 2025, a substantial deterioration from prior periods.
• GAAP diluted earnings per share was $(4.00), compared to $(0.08) in Q1 2025 and $0.44 in Q2 2024.
• Included a non-cash goodwill impairment charge of $67.3 million related to the curamik business.
• Total restructuring and impairment charges increased by $70.2 million sequentially to $76.1 million.
• Tax expense increased due to a $3.8 million valuation allowance recorded against deferred tax assets for certain European jurisdictions.
• Net sales of $202.8 million were down year-over-year from $214.2 million in Q2 2024.
• Gross margin of 31.6% was down year-over-year from 34.1% in Q2 2024.
• Adjusted EBITDA of $23.9 million was down year-over-year from $31.9 million in Q2 2024.

Risks

• Failure to capitalize on, volatility within, or other adverse changes with respect to growth drivers, such as delays in adoption or implementation of new technologies.
• Failure to successfully execute on the long-term growth strategy.
• Uncertain business, economic, and political conditions in the U.S. and abroad, particularly in China, South Korea, Germany, Belgium, England, and Hungary, where significant operations are maintained.
• Trade policy dynamics between the U.S. and other countries, especially China, including tariff impositions, associated countermeasures, and potential for U.S.-China supply chain decoupling.
• Fluctuations in foreign currency exchange rates.
• Ability to develop innovative products and the extent to which they are incorporated into end-user products and systems.
• The extent to which end-user products and systems incorporating products achieve commercial success.
• The ability and willingness of sole or limited source suppliers to deliver certain key raw materials, including commodities, in a timely and cost-effective manner.
• Business interruptions due to catastrophes or other similar events, such as natural disasters, war, terrorism, or public health crises.
• The impact of sanctions, export controls, and other foreign asset or investment restrictions.
• Failure to realize, or delays in the realization of anticipated benefits of acquisitions and divestitures due to, among other things, the existence of unknown liabilities or difficulty integrating acquired businesses.
• Ability to attract and retain management and skilled technical personnel.
• Ability to protect proprietary technology from infringement by third parties and/or allegations that technology infringes third-party rights.
• Changes in effective tax rates or tax laws and regulations in the jurisdictions in which operations occur.
• Failure to comply with financial and restrictive covenants in the credit agreement or restrictions on operational and financial flexibility due to such covenants.
• The outcome of ongoing and future litigation, including asbestos-related product liability litigation.
• Changes in environmental laws and regulations applicable to the business.
• Disruptions in, or breaches of, information technology systems.

Future Outlook

Rogers Corporation expects further improvement in results for the third quarter of 2025, with anticipated net sales between $200 million and $215 million, gross margin between 31.5% and 33.5%, GAAP earnings per diluted share between $0.00 and $0.40, and adjusted earnings per diluted share between $0.50 and $0.90. The company also projects 2025 capital expenditures to be between $30 million and $40 million and expects new cost reduction initiatives to yield over $13.0 million in annual run-rate savings.

Management Comments

• "As anticipated, second quarter sales increased sequentially due to incremental improvements across most end markets."
• "Sales, gross margin and adjusted earnings per share were all within our guidance ranges for the quarter."
• "We also utilized our strong balance sheet to repurchase $28 million of shares in Q2."
• "Looking ahead to the third quarter we expect further improvement in our results from slightly higher sales and cost reduction measures."
• "Today we also announced further cost savings initiatives targeted to our AES curamik business, in response to evolving market conditions."
• "We are intently focused on achieving more significant improvements in the Company's performance over the coming quarters as we improve sales growth with a more agile organization and increased speed of execution."

Industry Context

The announcement reflects the ongoing challenges in certain industrial sectors, particularly impacting the curamik business within the Advanced Electronics Solutions (AES) segment, necessitating strategic cost reductions. Despite these headwinds, the sequential sales growth in industrial, ADAS, aerospace and defense, and portable electronics suggests some pockets of recovery or resilience within the broader engineered materials market. The focus on cost reduction aligns with a broader industry trend of companies optimizing operations in response to evolving market conditions and supply chain dynamics.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or industry benchmarks to assess the results against.

Legal Proceedings

• Asbestos-related product liability litigation is mentioned as a risk factor that could affect the business, but no new or ongoing proceedings are detailed as an event in the filing.

Stakeholder Impact

• Shareholders are impacted by the significant net loss and impairment charge, but also by share repurchases and anticipated future cost savings.
• Employees in the curamik business in Eschenbach, Germany, are directly impacted by the announced cost reduction initiatives, which include employee severance costs, subject to consultation.
• Customers may experience potential impacts from changes in manufacturing operations in the curamik business, though the stated goal is to improve performance.
• Suppliers may be affected by changes in manufacturing operations and cost reduction efforts.

Next Steps

• Consultation process with applicable works council representatives for the Eschenbach, Germany facility regarding proposed cost reduction initiatives.
• Implementation of cost reduction initiatives in the curamik business.
• Expected cash outflows for restructuring in the second half of 2025 and bulk in 2026.
• Conference call to discuss Q2 2025 results on July 31, 2025, at 5:00 pm ET.

Key Dates

Recommendation

The significant non-cash impairment charge and net loss are concerning, reflecting challenges in a key business segment. However, the sequential improvements in sales and adjusted earnings, coupled with proactive cost reduction initiatives and a share repurchase program, suggest management is taking steps to address the issues. The future outlook indicates a path to recovery, but the immediate impact of restructuring costs and market conditions warrants a cautious approach. A "hold" recommendation allows investors to observe the effectiveness of the cost-cutting measures and the realization of anticipated improvements in the coming quarters before making a more definitive investment decision.

Keywords

Engineered Materials, Advanced Electronics Solutions, Elastomeric Material Solutions, curamik, Cost Reduction, Impairment Charge, Financial Results, Q2 2025, Rogers Corporation, ROG, Semiconductor, Automotive, Industrial, Aerospace, Defense, Portable Electronics, Wireless Infrastructure, Financial Reporting, SEC Filing